肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Autolus的下一代CAR-T细胞疗法更加安全有效

2019-04-04 不详 MedSci原创

Car-T细胞疗法嵌合抗原受体CD19
关注

英国生物技术公司Autolus正在开发下一代更安全，但同样有效的嵌合抗原受体（CAR）-T细胞疗法。该公司本周在美国癌症研究协会（AACR）上发布了其公司开发的CD19 CAR-T细胞疗法AUTO1治疗急性淋巴细胞白血病（ALL）成人患者的新数据。

英国生物技术公司Autolus正在开发下一代更安全，但同样有效的嵌合抗原受体（CAR）-T细胞疗法。该公司本周在美国癌症研究协会（AACR）上发布了其公司开发的CD19 CAR-T细胞疗法AUTO1治疗急性淋巴细胞白血病（ALL）成人患者的新数据。

诺华已经采用首批上市的CAR-T Kymriah治疗儿童和青少年ALL ，但目前尚未批准用于老年人的治疗。因为40岁以上患者，更易受到神经毒性和脑水肿等不良事件的困扰。

Autolus希望AUTO1能够改善CAR-T疗法的细胞毒性，临床结果显示8例接受AUTO1治疗的患者中没有出现严重细胞因子释放综合征（CRS）的报道。比较实验显示，吉利德/凯特的CAR-T疗法Yescarta的CRS发生率为23％，3级神经毒性为39％，而AUTO1仅为10％。

并且AUTO1的响应率也达到了88％，与Yescarta相比稍有改善。

分析师表示Autolus公司很可能"将药物转移到更早的治疗方案，或其他B细胞恶性肿瘤"，从而扩大市场机会。

数据披露后，公司股价从1.66美元上涨至2.63美元。该公司是近年来在英国出现的最强大的新生物技术公司之一，并在2018年成功上市，筹集了1.5亿美元。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1780250, encodeId=86991e80250b5, content=<a href='/topic/show?id=c7cd301495' target=_blank style='color:#2F92EE;'>#Autolus#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3014, encryptionId=c7cd301495, topicName=Autolus)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Mon Aug 05 04:14:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781288, encodeId=17ca1e8128850, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Jan 22 08:14:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291548, encodeId=ba561291548e1, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Sat Apr 06 06:14:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478012, encodeId=bf9614e801204, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Sat Apr 06 06:14:00 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2019-08-05 weiz

    #Autolus#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1780250, encodeId=86991e80250b5, content=<a href='/topic/show?id=c7cd301495' target=_blank style='color:#2F92EE;'>#Autolus#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3014, encryptionId=c7cd301495, topicName=Autolus)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Mon Aug 05 04:14:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781288, encodeId=17ca1e8128850, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Jan 22 08:14:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291548, encodeId=ba561291548e1, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Sat Apr 06 06:14:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478012, encodeId=bf9614e801204, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Sat Apr 06 06:14:00 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2020-01-22 仁心济世

    #CAR-#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1780250, encodeId=86991e80250b5, content=<a href='/topic/show?id=c7cd301495' target=_blank style='color:#2F92EE;'>#Autolus#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3014, encryptionId=c7cd301495, topicName=Autolus)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Mon Aug 05 04:14:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781288, encodeId=17ca1e8128850, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Jan 22 08:14:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291548, encodeId=ba561291548e1, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Sat Apr 06 06:14:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478012, encodeId=bf9614e801204, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Sat Apr 06 06:14:00 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2019-04-06 changjitao2009

    #Car-T细胞疗法#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1780250, encodeId=86991e80250b5, content=<a href='/topic/show?id=c7cd301495' target=_blank style='color:#2F92EE;'>#Autolus#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3014, encryptionId=c7cd301495, topicName=Autolus)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Mon Aug 05 04:14:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781288, encodeId=17ca1e8128850, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Jan 22 08:14:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291548, encodeId=ba561291548e1, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Sat Apr 06 06:14:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478012, encodeId=bf9614e801204, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Sat Apr 06 06:14:00 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2019-04-06 124984edm24暂无昵称

    #T细胞疗法#

    0

相关资讯

Nature：用CRISPR/Cas9技术将肿瘤抗原受体编辑进T细胞TRAC基因位点，增强杀死癌细胞的能力

运用CRISPR/Cas9编辑的CAR-T细胞对于急性淋巴细胞白血病（Acute lymphoblastic leukemia）有更好的疗效。

Blood：抑制GM-CSF不仅可增强CAR-T细胞功能，还可减轻细胞因子释放综合征和神经炎症

嵌合抗原受体T细胞疗法（CAR-T）是癌症疗法的新秀，但其应用受到其相关毒性作用的限制。包括细胞因子释放综合征（CRS）和神经毒性。虽然IL-6R拮抗剂托珠单抗已被批准用于治疗CRS，但尚无认可的用于治疗CD19靶向CAR-T（CART19）细胞疗法相关的神经毒性的药物。近期，有研究表明单核细胞和巨噬细胞促进CAR-T细胞治疗后的CRS和神经毒性的进展。中和粒细胞巨噬细胞集落刺激因子(GM-CSF

陈文明教授：复发/难治多发性骨髓瘤的诊疗及CAR-T细胞疗法初探

随着蛋白酶体抑制剂、免疫抑制剂在新诊断多发性骨髓瘤（MM）的广泛应用，MM患者的缓解时间以及生存期逐渐延长，但MM患者最终都会复发，并且复发后的治疗选择更为困难。